French Endocrine Society Guidance on endocrine side-effects of immunotherapy by F. Castinetti et al.
French Endocrine Society Guidance on endocrine side-
effects of immunotherapy
Submitted by Beatrice Guillaumat on Tue, 11/27/2018 - 15:33
Titre French Endocrine Society Guidance on endocrine side-effects of immunotherapy
Type de
publication Article de revue
Auteur
Castinetti, Frederic [1], Albarel, Frédérique [2], Archambeaud, Françoise [3],
Bertherat, Jerome [4], Bouillet, Benjamin [5], Buffier, Perrine [6], Briet, Claire [7],
Cariou, Bertrand [8], Caron, Philippe [9], Chabre, Olivier [10], Chanson, Philippe [11],
Cortet, Christine [12], Do Cao, Christine [13], Drui, Delphine [14], Haissaguerre,
Magalie [15], Hescot, Segolene [16], Illouz, Frédéric [17], Kuhn, Emmanuelle [18],
Lahlou, Najiba [19], Merlen, Emilie [20], Raverot, Veronique [21], Smati, Sarra [22],
Vergès, Bruno [23], Borson-Chazot, Françoise [24]
Editeur BioScientifica
Type Article scientifique dans une revue à comité de lecture
Année 2018
Langue Anglais









The management of cancer patients has changed due to the considerably more
frequent use of immune checkpoint inhibitors (ICPI). However, the use of ICPI has a
risk of side-effects, particularly endocrine toxicity. Since the indications for ICPI are
constantly expanding due to their efficacy, it is important that endocrinologists and
oncologists know how to look for this type of toxicity and how to treat it when it
arises. In view of this, the French Endocrine Society initiated the formulation of a
consensus document on ICPI-related endocrine toxicity. In this paper, we will
introduce data on the general pathophysiology of endocrine toxicity, we will then
outline expert opinion focusing primarily on methods for screening, management and
monitoring for endocrine side-effects in patients treated by ICPI. We will then look in
turn at endocrinopathies that are induced by ICPI including dysthyroidism,
hypophysitis, primary adrenal insufficiency and fulminant diabetes. In each chapter,
expert opinion will be given on the diagnosis, management and monitoring for each
complication. These expert opinions will also discuss the methodology for categorizing
these side-effects in oncology using 'Common terminology criteria for adverse events'
(CTCAE) and the difficulties in applying this to endocrine side-effects in the case of
these anti-cancer therapies. This is shown in particular by certain recommendations
that are used for other side-effects (high-dose corticosteroids, contra-indicated in ICPI
for example), and that cannot be considered as appropriate in the management of









































Publié sur Okina (http://okina.univ-angers.fr)
